Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
AdAlta has announced a collaboration with Carina Biotech, a private Australian company, in which the two companies will work together to develop chimeric antigen receptor T cell (CAR-T) therapies for solid tumours. Under the agreement, AdAlta will discover and optimise proprietary i-bodies on up to five undisclosed tumour antigen targets, from which Carina will generate bi-specific CAR-T cells and identify optimal candidates. We believe the CAR-Ts will be autologous, generated from a patient’s o...
AdAlta has announced a collaboration with Carina Biotech, a private Australian company, in which the two companies will work together to develop chimeric antigen receptor T cell (CAR-T) therapies for solid tumours. Under the agreement, AdAlta will discover and optimise proprietary i-bodies on up to five undisclosed tumour antigen targets, from which Carina will generate bi-specific CAR-T cells and identify optimal candidates. We believe the CAR-Ts will be autologous, generated from a patient’s o...
AdAlta has announced it will be moving forward with an inhaled formulation of AD-214 into efficacy studies in patients with idiopathic pulmonary fibrosis (IPF) rather than the original intravenous (IV) formulation. Preclinical studies with a radiolabelled version of AD-214 have indicated that IV dosing leads to much of the administered drug being rapidly distributed through the liver and cleared, rendering it unavailable to deliver a therapeutic effect. The company believes the advantages of an ...
AdAlta recently announced that its collaboration with GE Healthcare is moving into the next stage as GE Healthcare has selected multiple i-bodies from AdAlta’s platform to progress into preclinical development. Additionally, the two companies have agreed to amend their agreement as AdAlta will now provide manufacturing support for both preclinical and clinical development for these candidates. It will also be conducing certain preclinical studies. These activities will earn AdAlta additional res...
Part A of the AD-214 Phase I has been completed in 42 healthy volunteers who received a single dose of either AD-214 or placebo. There were no dose limiting or serious adverse events and no concerning clinical laboratory results. Additionally, AD-214 pharmacokinetics increased proportionally with the dose with evidence seen of CXCR4 engagement and high sustained receptor occupancy. AdAlta will now be investigating dosing every two weeks for AD-214 in the Part B portion of the study.
Edison Investment Research Limited AdAlta (1AD): Initiation - Targeting IPF with its i-body platform 22-Feb-2021 / 20:00 GMT/BST London, UK, 22 February 2021 AdAlta (1AD): Initiation - Targeting IPF with its i-body platform AdAlta is a clinical-stage company that uses its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), which is in the healthy volunteer portion of a 98-sub...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.